Relative Bioavailability and Food Effect Study of IX-01 Capsules in Healthy Men

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: IX-01

Registration Number: NCT02139826

Lead Sponsor: Ixchelsis Limited

Brief Summary: The purpose of this study is to compare the absorption and blood levels of IX-01 when given as a capsule compared to liquid form, and how food affects the absorption in healthy men.

Detailed Description: Not available

Recruitment & Eligibility

Status: COMPLETED

Sex: Male

Target Recruitment: 12

Inclusion Criteria

A body mass index (Quetelet index) in the range 18-30 kilograms/meters squared (kg/m2)
Body Mass Index = weight [kg] divided by (height [m])2
Total body weight greater than (>)50 kg at screening
Ability to communicate satisfactorily with the investigator and to participate in, and comply with the requirements of, the entire trial
Participants and their partners must be willing to use adequate forms of contraception and to comply with the contraception requirements during the trial and for 4 months after the last dose of medication
Willingness to give written consent to have data entered into The Over Volunteering Prevention System

Exclusion Criteria

Clinically relevant abnormal history, physical findings, ECG, or laboratory values at the pre-trial screening assessment, including:
- Lipid and/or liver function test results >1.25 x Upper Limit of Normal (ULN) or other clinical laboratory blood biochemistry test results outside the normal reference range unless discussed and approved by sponsor
- International normalised ratio (INR) of >1.2 or a platelet count < 150 x 109/Liter
- History of unexplained syncope
- Family history of unexplained sudden death, or sudden death due to long QT syndrome
- Fridericia Correction Formula (QTcF) interval >450 milliseconds (msec) at screening
- Bundle branch block and other conduction abnormalities, other than mild first degree atrio-ventricular block
- Irregular rhythms other than sinus arrhythmia or occasional supraventricular ectopic beats
- T-wave configuration of insufficient quality for determination of QT interval, as assessed by the investigator
Presence of acute or chronic illness or history of chronic illness sufficient to invalidate participation in the trial
Impaired gastrointestinal, endocrine, thyroid, hepatic, cardiovascular, respiratory, haematological, renal or neurological function, diabetes mellitus, coronary heart disease, or history of any psychotic mental illness
Surgery (for example (e.g.) stomach bypass) or medical condition that might affect absorption, metabolism or elimination of medicines
Any skin condition, abnormality of the lumbar spine, medical or surgical condition that would preclude lumbar puncture (e.g. coagulopathy, local or systemic infection, left ventricular outflow obstruction, aortic stenosis, previous back surgery)
Presence or history of severe adverse reaction to any drug
Use of any prescription or over-the-counter medicine during the 14 days before the first dose of trial medication, or intention to use any medicine during the trial, with the exception of short courses of medication considered by the investigator not to interfere with the safety of the participant or the integrity of the trial data (such as acetaminophen (paracetamol))
Current use of any herbal remedy or nutritional supplement, or intention to use any such product during the study
Participation in another clinical trial of a new chemical entity or a prescription medicine within the previous 3 months.
Previous participation in this trial or any other clinical trial of an oxytocin receptor antagonist
Presence or history of drug or alcohol abuse, or intake of more than 21 units of alcohol weekly or more than 5 cigarettes daily
Blood pressure and heart rate in supine position at the screening examination outside the ranges 100-130 millimeters of mercury (mm Hg) systolic, 60-90 mm Hg diastolic; heart rate 50-100 beats/minute. Measurements must be made in duplicate, and all values must fall within the acceptable ranges
Possibility that the participant will not cooperate with the requirements of the protocol
Evidence of drug abuse on urine testing
Positive test for hepatitis B, hepatitis C, Human Immunodeficiency Virus 1 (HIV1) or Human Immunodeficiency Virus 2 (HIV2)
Loss of more than 400 mL blood during the 3 months before the trial, e.g. as a blood donor
Objection by General Practitioner (GP), on medical grounds, to participant entering trial
Employee of the investigator site or any company involved in sponsoring, organizing or conducting the trial, or immediate family of the employee

Study & Design

Study Type: INTERVENTIONAL

Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
IX-01 Capsule while Fasting	IX-01	Singe oral dose of 800 milligrams of IX-01 as a capsule, while fasting, in 1 of 3 treatment periods
IX-01 Aqueous Dispersion while Fasting	IX-01	Single oral dose of 800 milligrams IX-01 as an aqueous dispersion, while fasting in 1 of 3 treatment periods
IX-01 Capsule after Food	IX-01	Single oral dose of 800 milligrams IX-01 as a capsule, after food, in 1 of 3 treatment periods

Primary Outcome Measures

Name	Time	Method
Relative Bioavailability (Frel) of a Capsule Formulation of IX-01 in the Fed State Compared to the Fasted State, as Calculated by a Ratio of Area Under the Plasma Concentration Time Curve From Time 0 to Infinity	Pre-dose up to 96 hours post dose
Relative Bioavailability (Frel) of a Capsule Compared With a Liquid Formulation of IX-01 While Fasting, as Calculated by a Ratio of Peak Plasma Concentrations	Pre-dose up to 96 hours post dose
Area Under the Plasma Concentration Time Curve From Time 0 to the Time of the Last Measurable Sample of IX-01	Pre-dose to the time of the last measurable sample
Concentration of IX-01 in Cerebrospinal Fluid (CSF) After a Single Dose of the Liquid Formulation of IX-01	1, 2, 4 and 6 hours after dosing	Listed by time point of 1, 2, 4, 6 hours post dose
Relative Bioavailability (Frel) of a Capsule Compared to a Liquid Formulation of IX-01 While Fasting, as Calculated by a Ratio of Area Under the Plasma Concentration Time Curve From Time 0 to Infinity	Pre-dose up to 96 hours post dose
Relative Bioavailability (Frel) of a Capsule Formulation of IX-01 in a Fed State Compared to a Fasted State, as Calculated by a Ratio of Peak Plasma Concentrations	Pre-dose up to 96 hours post dose
Area Under the Plasma Concentration Time Curve From Time 0 to Infinity, Following a Single Dose of IX-01	Pre-dose and up to 96 hours post dose
Peak Plasma Concentration (Cmax) of IX-01	Pre-dose and up to 96 hours post dose
Time to Peak Plasma Concentration (Tmax) of IX-01	Pre-dose up to 96 hours post dose
Elimination Half Life (t1/2) of IX-01	Pre-dose up to 96 hours post dose
Elimination Rate Constant (Kel) of IX-01	Pre-dose up to 96 hours post last dose